Department of Neurosurgery, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, 59 Boulevard Pinel, 69667, Bron, France.
Claude Bernard University Lyon 1, Lyon, France.
J Cancer Res Clin Oncol. 2021 Jun;147(6):1843-1856. doi: 10.1007/s00432-020-03474-6. Epub 2021 Jan 5.
To analyze the outcomes and predictors in a large series of cerebellar glioblastomas in order to guide patient management.
The French brain tumor database and the Club de Neuro-Oncologie of the Société Française de Neurochirurgie retrospectively identified adult patients with cerebellar glioblastoma diagnosed between 2003 and 2017. Diagnosis was confirmed by a centralized neuropathological review.
Data from 118 cerebellar glioblastoma patients were analyzed (mean age 55.9 years, 55.1% males). The clinical presentation associated raised intracranial pressure (50.8%), static cerebellar syndrome (68.6%), kinetic cerebellar syndrome (49.2%) and/or cranial nerve disorders (17.8%). Glioblastomas were hemispheric (55.9%), vermian (14.4%) or both (29.7%). Hydrocephalus was present in 49 patients (41.5%). Histologically, tumors corresponded either to IDH-wild-type or to K27-mutant glioblastomas. Surgery consisted of total (12.7%), subtotal (35.6%), partial resection (33.9%) or biopsy (17.8%). The postoperative Karnofsky performance status was improved, stable and worsened in 22.4%, 43.9% and 33.7% of patients, respectively. Progression-free and overall survivals reached 5.1 months and 9.1 months, respectively. Compared to other surgical strategies, total or subtotal resection improved the Karnofsky performance status (33.3% vs 12.5%, p < 0.001), prolonged progression-free and overall survivals (6.5 vs 4.3 months, p = 0.015 and 16.7 vs 6.2 months, p < 0.001, respectively) and had a comparable complication rate (40.4% vs 31.1%, p = 0.29). After total or subtotal resection, the functional outcomes were correlated with age (p = 0.004) and cerebellar hemispheric tumor location (p < 0.001) but not brainstem infiltration (p = 0.16).
In selected patients, maximal resection of cerebellar glioblastoma is associated with improved onco-functional outcomes, compared with less invasive procedures.
分析大量小脑胶质母细胞瘤患者的治疗效果和预测因素,以指导患者的管理。
法国脑瘤数据库和法国神经外科学会神经肿瘤学俱乐部回顾性分析了 2003 年至 2017 年间诊断为小脑胶质母细胞瘤的成年患者。诊断通过集中的神经病理学审查确认。
分析了 118 例小脑胶质母细胞瘤患者的数据(平均年龄 55.9 岁,55.1%为男性)。临床表现与颅内压升高(50.8%)、静止性小脑综合征(68.6%)、运动性小脑综合征(49.2%)和/或颅神经障碍(17.8%)有关。胶质母细胞瘤位于大脑半球(55.9%)、蚓部(14.4%)或两者兼有(29.7%)。49 例患者存在脑积水(41.5%)。组织学上,肿瘤对应 IDH-野生型或 K27-突变型胶质母细胞瘤。手术方式包括全切除(12.7%)、次全切除(35.6%)、部分切除(33.9%)或活检(17.8%)。术后卡诺夫斯基表现状态改善、稳定和恶化的患者分别占 22.4%、43.9%和 33.7%。无进展生存期和总生存期分别为 5.1 个月和 9.1 个月。与其他手术策略相比,全切除或次全切除可改善卡诺夫斯基表现状态(33.3% vs 12.5%,p<0.001),延长无进展生存期和总生存期(6.5 个月 vs 4.3 个月,p=0.015 和 16.7 个月 vs 6.2 个月,p<0.001),且并发症发生率相当(40.4% vs 31.1%,p=0.29)。在全切除或次全切除后,功能结果与年龄(p=0.004)和小脑大脑半球肿瘤位置(p<0.001)相关,但与脑干浸润无关(p=0.16)。
在选择的患者中,与侵袭性较小的手术相比,最大程度切除小脑胶质母细胞瘤与改善肿瘤相关的功能预后相关。